金斯瑞生物科技(01548)：CARVYKTI于截至2025年9月30日止季度产生贸易销售净额...

Core Viewpoint - Kingsray Biotechnology (01548) announced that CARVYKTI® is expected to generate trade sales net revenue of approximately $524 million for the quarter ending September 30, 2025, based on the collaboration and licensing agreement established with Janssen Biotech, Inc. on December 21, 2017 [1]. Group 1 - Kingsray Biotechnology's CARVYKTI® is projected to achieve significant sales revenue [1]. - The collaboration with Janssen Biotech, Inc. plays a crucial role in the commercialization of CARVYKTI® [1]. - The sales forecast is based on a previously established agreement from December 2017 [1].